## NBIX: Neurocrine Biosciences, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.27 indicates fundamental undervaluation.

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($145.89)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Arrowstreet Capital Limited Partnership Acquires 58,562 Shares of Neurocrine Biosciences, Inc. $NBIX**
- Source: MarketBeat | 20251209T080950 | Neutral | Relevance: 99%
- Arrowstreet Capital Limited Partnership increased its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 87.9% in the second quarter, now owning 125,162 shares worth $15.73 million. Other institutional investors also adjusted their positions, and company insiders have sold shares totaling over $4.9 million in the last three months. Neurocrine Biosciences reported strong Q3 earnings, beating analyst estimates, and analysts have set new price targets, with a consensus "Moderate Buy" rating.

**2. How Neurocrine Biosciences Inc. (NBIX) Affects Rotational Strategy Timing**
- Source: Stock Traders Daily | 20251210T230400 | Bullish | Relevance: 98%
-  Neurocrine Biosciences Inc. (NBIX) shows strong sentiment across all horizons, supporting an overweight bias. The article provides institutional trading strategies, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis, all generated by AI models. It highlights key findings like an exceptional short setup targeting 10.9% downside versus 0.3% risk.

**3. Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $180.00**
- Source: MarketBeat | 20251209T110933 | Bullish | Relevance: 98%
- Royal Bank of Canada raised its price target for Neurocrine Biosciences (NASDAQ:NBIX) to $180.00 from $160.00, maintaining an "outperform" rating and implying a 13.05% upside. This follows stronger-than-expected Q3 results where the company reported EPS of $2.17 and revenue of $794.9 million, exceeding analyst estimates. Despite recent insider stock sales totaling approximately $4.93 million, institutional ownership remains high at 92.59%.

**4. Neurocrine Biosciences (NASDAQ:NBIX) Hits New 12-Month High Following Analyst Upgrade**
- Source: MarketBeat | 20251209T111010 | Bullish | Relevance: 98%
-  Neurocrine Biosciences (NASDAQ:NBIX) reached a new 52-week high after Royal Bank of Canada and other analysts raised their price targets, indicating a "Moderate Buy" consensus. The company reported strong Q3 results with EPS of $2.17 and revenue up 27.8% year-over-year, supporting analyst optimism. Despite some insider selling, institutional ownership remains high with significant increases from funds like Dodge & Cox and JPMorgan.

**5. Neurocrine Biosciences stock hits 52-week high at $157.88**
- Source: Investing.com | 20251209T110933 | Bullish | Relevance: 97%
-  Neurocrine Biosciences (NBIX) stock achieved a 52-week high of $157.88, reflecting an 87% increase from its 52-week low and a 21.94% appreciation over the past year. This growth is attributed to strong investor confidence, a $15.7 billion market cap, 19.6% revenue growth, and positive analyst ratings, with RBC Capital, TD Cowen, and Stifel raising their price targets due to the strong performance and competitive advantage of its drug, Ingrezza. The company's strategic initiatives, share buyback program, and favorable market conditions, including less severe-than-expected price cuts for a competitor's drug under the Inflation Reduction Act, further bolster its outlook.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Stifel | $188 | $183 | +3% |
| 2025-12-08 | RBC Capital | $180 | $160 | +12% |
| 2025-12-05 | TD Cowen | $200 | $175 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Stifel | main | Buy |
| 2025-12-08 | RBC Capital | main | Outperform |
| 2025-12-05 | TD Cowen | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 4 ($1.77M) |
| Sells | 4 ($3.24M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 12.7% (-1.9%)
- Vanguard Group Inc: 9.7% (-1.0%)
- JPMORGAN CHASE & CO: 9.5% (+122.0%)
- Dodge & Cox Inc.: 5.6% (-0.2%)
- State Street Corpora: 4.4% (-2.7%)

### Key Risks

1. Insider selling cluster: $3.2M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +10%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.27 indicates undervaluation relative to growth. Forward P/E 16.9x attractive for 33% earnings growth. Quality metrics strong (margin 16%). Balance sheet: strong liquidity (3.4x), low leverage (D/E 0.42). Analyst sentiment positive (3 raises, avg +10%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $15.4B |
| Beta | 0.27 |
| 52W Range | $84.23 - $160.18 |
| Short Interest | 5.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.27 |
| Forward P/E | 16.9 |
| Current P/E | 22.5 |
| YoY Growth | 32.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 3.4% to 2.2% (-1.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.8pp (needs >4.0% for momentum thesis). MRS_5 (-0.3%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 4.4% shows strong absolute momentum above own 20MA. Outperforming sector by 4.5pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.66), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.25% (CS: 61) | Neutral |
| RSI_14 | 62.8 | Neutral |
| MACD Histogram | 0.66 | Bullish |
| vs SMA20 | 1.044x | Above |
| vs SMA50 | 1.069x | Above |
| vs SMA200 | 1.202x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $154.75
- **Stop Loss:** $145.89 (5.7% risk)
- **Target:** $172.47 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 155
- **Position Value:** $23,986.25
- **Portfolio %:** 23.99%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-05 (Est: $2.41)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.07 | $2.17 | +4.9% |
| 2025Q2 | $1.50 | $1.65 | +9.6% |
| 2025Q1 | $1.09 | $0.70 | -36.0% |
| 2024Q4 | $1.93 | $1.69 | -12.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*